Put the EUA for Baricitinib Plus Remdesivir in Perspective
The oral rheumatoid arthritis med baricitinib (Olumiant) is now authorized to treat COVID-19 in hospitalized patients.
It’s a Janus kinase (JAK) inhibitor that blocks cytokines to decrease inflammation. Plus it may have antiviral effects.
Explain that evidence suggests ADDING baricitinib to remdesivir (Veklury) reduces recovery time by 1 day...compared to remdesivir alone. But it’s too soon to say if the combo reduces mortality.